1-3 of 3
Tanja Rixecker
Close
Sort by
Journal Articles

Suboptimal dosing of rituximab in male and female patients with DLBCL

Clinical Trials & Observations
Michael Pfreundschuh, Carsten Müller, Samira Zeynalova, Evelyn Kuhnt, Martin H. J. Wiesen, Gerhard Held, Tanja Rixecker, Viola Poeschel, Carsten Zwick, Marcel Reiser, Norbert Schmitz, Niels Murawski
Journal: Blood
Blood (2014) 123 (5): 640–646.
https://doi.org/10.1182/blood-2013-07-517037
Published: 2014
Includes: Supplemental data
Journal Articles

Parenthood in Long-Term Survivors After CHOEP Treatment for Aggressive Lymphoma Is Not Significantly Impaired in Comparison to the General Population. Results From the Mabthera International Trial (MInT) and the DSHNHL NHLB1 Study

Julia Meissner, MD, Sascha Dietrich, MD, Marita Ziepert, PhD, Evelyn Kuhnt, Tanja Rixecker, Mathias Witzens-Harig, MD, Michael Pfreundschuh, MD, Anthony D Ho, MD
Journal: Blood
Blood (2012) 120 (21): 3649.
https://doi.org/10.1182/blood.V120.21.3649.3649
Published: 2012
Journal Articles

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Clinical Trials & Observations
Carsten Müller, Niels Murawski, Martin H. J. Wiesen, Gerhard Held, Viola Poeschel, Samira Zeynalova, Michael Wenger, Christina Nickenig, Norma Peter, Eva Lengfelder, Bernd Metzner, Tanja Rixecker, Carsten Zwick, Michael Pfreundschuh, Marcel Reiser
Journal: Blood
Blood (2012) 119 (14): 3276–3284.
https://doi.org/10.1182/blood-2011-09-380949
Published: 2012